Pharmaceutical promotion is one of the few categories where the regulator, not the creative director, sets the shape of the work. Advertising for a prescription product carries obligations about what must be said alongside the claim, and every asset passes an internal medical, legal and regulatory review before it reaches a reader. That single fact explains most of what looks strange about this market to an outsider: why campaigns take longer, why agencies staff differently, and why the same brief costs a multiple of what it would in consumer goods. A buyer who prices on creative firepower alone will choose the wrong partner.
The categories of agency, and which brief each suits
Four kinds of firm compete for this work. Large network agencies inside global holding companies bring scale, established review workflow and the ability to run a launch across markets, at the highest cost. Independent healthcare specialists trade some of that scale for senior attention and faster cycles, and often win mid sized brands. Medical communications firms sit closer to the science, producing publication plans, congress materials and content for healthcare professionals rather than consumer campaigns, and are the right choice for a professional audience. Digital and media specialists handle targeting, programmatic buying and point of care channels but usually need a lead agency alongside them. The mistake buyers make is briefing one type for another's job, most commonly asking a consumer led shop to produce healthcare professional materials. Ask each candidate directly which of these four they are, and be sceptical when the answer is all of them.
Regulatory review is the schedule and much of the cost
Federal regulations on prescription drug advertising set out requirements for how promotional material must present a product, including the presentation of risk information alongside effectiveness claims, and the text is public in the electronic Code of Federal Regulations at 21 CFR Part 202. What that means commercially is that every concept, script and layout runs through a medical, legal and regulatory committee, often several times, and revisions are expensive because each one restarts the cycle. Agencies experienced in the category design for that reality: they bring annotated references from the first concept, they present fewer and better developed routes, and they build review time into the timeline honestly rather than discovering it. When comparing candidates, ask how many review rounds their last launch took and what they did to reduce them. An agency that answers with a specific number has lived it.
How to compare proposals in a market with no published pricing
Pharma agencies almost never publish rates, so comparison has to be constructed rather than looked up. Send every candidate an identical written scope and ask for a staffing plan against it: named roles, seniority, hours per month, and which functions are in house versus subcontracted. Then ask what happens to that plan when review adds a round. Ask which of the people in the pitch will actually work on the account, a question that separates agencies more sharply in this category than in any other because pitch teams here are frequently a different population from delivery teams. Ask for references from a brand at a similar stage, since launch work and mature brand work require different capabilities. Buyers assembling a wider roster of advertising companies should run the same identical scope method across categories, because it is the only way to make quotes that were never designed to be comparable sit side by side.
Data, targeting and the boundaries around it
Much of what a pharma media plan does now is audience targeting, and the boundaries there are stricter than in general consumer advertising. Data about individuals' health is sensitive, targeting practices that infer a diagnosis carry real risk, and general advertising rules on substantiation still apply to anything said about a product. Ask candidates how they handle audience construction, what data sources they use and under what agreements, and how they keep promotional material for professional audiences separate from consumer facing material. Ask what their process is for material that mentions a condition without naming a product, since unbranded disease awareness work has its own conventions. The good answer is procedural and specific. A vague reassurance about being fully compliant is a sign that compliance is somebody else's department.
Questions people ask about pharma advertising agencies
Do we need a healthcare specialist agency or will a strong general agency do?
For anything promotional about a prescription product, specialists earn their fee in the review process rather than in the creative. A general agency can produce excellent work and then spend months learning what will not clear review, at your cost. Unbranded or corporate work has more room for a generalist.
How long does a campaign take from brief to launch?
Substantially longer than consumer work, because the medical, legal and regulatory review cycle sits between every stage and each revision restarts part of it. Ask candidates for the actual elapsed timeline on their most recent comparable launch, including review rounds, rather than an idealised process diagram.
What should the agreement say about materials and references?
It should name who owns the artwork, the annotated reference packs and the review submissions, and specify what is handed over and in what format if the relationship ends. Reference packs represent a great deal of accumulated work and rebuilding them at a new agency is a real and avoidable cost.
Should media buying sit with the creative agency?
It can, but insist on transparent reporting of what was bought and at what cost regardless of structure. In point of care and endemic health media the inventory is specialised and pricing is opaque, so the question to press is how the agency verifies delivery and what it discloses about its own margin on the buy.